Vaxcyte Balance Sheet Health
Financial Health criteria checks 6/6
Vaxcyte has a total shareholder equity of $3.2B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $3.4B and $178.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$1.67b |
| Equity | US$3.20b |
| Total liabilities | US$178.08m |
| Total assets | US$3.38b |
Recent financial health updates
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans
Mar 24
We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
Dec 08We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate
Aug 24Vaxcyte (NASDAQ:PCVX) Has Debt But No Earnings; Should You Worry?
May 10Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans
Dec 27We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
Sep 12Recent updates
Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity
Mar 31Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans
Mar 24Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy
Jan 15We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
Dec 08Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy
Sep 06We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate
Aug 24Vaxcyte (NASDAQ:PCVX) Has Debt But No Earnings; Should You Worry?
May 10Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans
Dec 27We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
Sep 12Here's Why We're Not Too Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Situation
May 30We Think Vaxcyte (NASDAQ:PCVX) Can Afford To Drive Business Growth
Dec 22Vaxcyte appoints new CBO, CMO
Oct 11Financial Position Analysis
Short Term Liabilities: PCVX's short term assets ($1.7B) exceed its short term liabilities ($97.0M).
Long Term Liabilities: PCVX's short term assets ($1.7B) exceed its long term liabilities ($81.1M).
Debt to Equity History and Analysis
Debt Level: PCVX is debt free.
Reducing Debt: PCVX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PCVX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PCVX has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 49.8% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 07:53 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vaxcyte, Inc. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Thomas Shrader | BTIG |
| Carter Gould | Cantor Fitzgerald & Co. |